PO.TB10.12 · 肿瘤生物学
对细胞外酸性pH的耐受促进肿瘤可塑性
Tolerance to extracellular acidic pH facilitates tumor plasticity
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
癌细胞尽管有氧可用仍维持糖酵解代谢,导致由质子和乳酸分泌增强所介导的酸性微环境。我们此前报道,这种酸性肿瘤微环境诱导胆固醇生物合成通路和多胺通路的激活。尽管这些代谢适应已被充分记载,但控制酸性条件下细胞存活的机制仍知之甚少。我们首先证明,严重酸化(pH 5.6)触发坏死性凋亡细胞死亡,而中度酸化(pH 6.8)阻止坏死性凋亡并允许非贴壁依赖性存活和肿瘤起始。在pH 5.6时,PANC1和MIA-PaCa2胰腺癌细胞表现出RIP1和MLKL的磷酸化,Calcein-AM活细胞成像证实了膜破裂性细胞死亡;这些特征在pH 6.8时未观察到。此外,当将PANC1悬浮细胞(pH 7.4或pH 6.8)皮下注射入SCID/SCID小鼠时,仅在植入pH 6.8悬浮细胞的小鼠中于第7天观察到肿瘤起始。比较pH 6.8和pH 7.4下贴壁细胞与悬浮细胞的RNA测序显示,补体通路特异性地在pH 6.8悬浮细胞中激活,提示补体抑制可能选择性地清除耐酸癌细胞。在慢性酸暴露的PANC1细胞中进行的全基因组CRISPR-Cas9敲除筛选鉴定出FAM129C为耐酸性和细胞存活的关键调控因子。在异种移植模型中,FAM129C过表达导致PIGR下调。相反,在过表达PIGR的小鼠胰腺Pan02细胞中,免疫分析显示免疫细胞浸润增强,尤其是巨噬细胞浸润增加。最后,我们评估了将抗PD-L1抗体(alphaPD-L1)与补体抑制剂PMX53联合的治疗疗效。这种协同治疗显著抑制了PIGR过表达的Pan02肿瘤的生长。免疫组织化学显示,联合治疗增加了肿瘤微环境内IFN-gamma⁺ CD8⁺ T细胞并减少了巨噬细胞浸润。我们的发现揭示了一条此前未被表征的通路,其规避坏死性凋亡细胞死亡并在酸性应激下增强细胞可塑性,通过pH依赖性细胞死亡调控为癌症治疗提供新的治疗途径。
查看英文原文 English abstract
Cancer cells maintain glycolytic metabolism despite oxygen availability, resulting in an acidic microenvironment mediated by enhanced proton and lactate secretion. We have previously reported that this acidic tumor microenvironment induces the activation of the cholesterol biosynthesis pathway and polyamine pathway. Although these metabolic adaptations have been well documented, the mechanisms governing cell survival under acidic conditions are poorly understood. We first demonstrated that severe acidification (pH 5.6) triggered necroptotic cell death, whereas moderate acidification (pH 6.8) prevented necroptosis and allowed anchorage-independent survival and tumor initiation. At pH 5.6, PANC1 and MIA-PaCa2 pancreatic cancer cells exhibited phosphorylation of RIP1 and MLKL, and Calcein-AM live imaging confirmed membrane-rupturing cell death; these features were not observed at pH 6.8. In addition, when PANC1 floating cells (pH 7.4 or pH 6.8) were subcutaneously injected into SCID/SCID mice, tumor initiation was observed only in the mice implanted with pH 6.8 floating cells by day 7. RNA sequencing comparing adherent and floating cells at pH 6.8 and pH 7.4 revealed activation of the complement pathway specifically in pH 6.8 floating cells, suggesting that complement inhibition may selectively eliminate acid-tolerant cancer cells. A genome-wide CRISPR-Cas9 knockout screen in chronically acid-exposed PANC1 cells identified FAM129C as a critical regulator of acid tolerance and cell survival. In xenograft models, FAM129C overexpression led to downregulation of PIGR. Conversely, in murine pancreatic Pan02 cells overexpressing PIGR, immune profiling showed enhanced immune cell infiltration, particularly increased macrophage infiltration. Finally, we evaluated the therapeutic efficacy of combining an anti-PD-L1 antibody (alphaPD-L1) with PMX53, a complement inhibitor. This synergistic treatment markedly suppressed tumor growth in PIGR-overexpressing Pan02 tumors. Immunohistochemistry revealed that the combination therapy increased IFN-gamma⁺ CD8⁺ T cells and reduced macrophage infiltration within the tumor microenvironment. Our findings reveal a previously uncharacterized pathway that evades necroptotic cell death and enhances cellular plasticity under acidic stress, offering new therapeutic approaches for cancer treatment through pH-dependent cell death modulation.
利益披露 Disclosure
M. Hasegawa, None..
B. Xu, None..
F. Cai, None..
R. Cui, None..
R. Ando, None..
K. Matsumoto, None..
C. Iwabuchi-Yoshida, None..
K. Yamagata, None..
R. Tsuchida, None..
T. Osawa, None.